Volatility & Risk
TransEnterix has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, TransEnterix’s competitors have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.
Valuation & Earnings
This table compares TransEnterix and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| TransEnterix | $8.53 million | -$154.20 million | -0.04 |
| TransEnterix Competitors | $59.54 million | -$32.15 million | 4.35 |
TransEnterix’s competitors have higher revenue and earnings than TransEnterix. TransEnterix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
Profitability
This table compares TransEnterix and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransEnterix | -2,149.15% | -83.74% | -64.94% |
| TransEnterix Competitors | -672.41% | -133.75% | -59.01% |
Summary
TransEnterix competitors beat TransEnterix on 7 of the 9 factors compared.
About TransEnterix
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.
